The U.S. Supreme Court has begun deliberations over the case that will determine accessibility to the most commonly used abortion medication in the country, mifepristone. The Food and Drug Administration v. Alliance for Hippocratic Medicine began oral arguments on Tuesday, March 26, and a decision is expected by the summer, according to The Washington Post. 

In 2023, mifepristone became the most commonly used abortion treatment in the United States, accounting for over 60% of abortion treatments, the Post reported. It has become a more accessible abortion treatment, particularly for Americans living in rural areas where there are few clinics and for those living in states with strict abortion laws.